ResearcherLMU KlinikumActive in the last 2 years
Kathrin Heinrich
Matched on ORCID iD 0000-0003-3580-2313; OpenAlex author ID A5068912139. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 42
2023: 4 papers · 2024: 1 paper · 2025: 1 paper
Papers 6
- Sustained Clinical Response to Olaparib in a Patient with Metastatic Pancreatic Cancer and Somatic ATM Mutation R2034Ter: A Case Report. Co-author DOI 10.1159/000545975↗
- Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical trial. Co-author DOI 10.1016/j.ejca.2024.113926↗
- In-vitro model to mimic T cell subset change in human PDAC organoid co-culture. Co-author DOI 10.1007/s00432-023-05100-7↗
- Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. Co-author DOI 10.1007/s11523-023-00950-0↗
- Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort. Co-author DOI 10.1016/j.ejca.2023.04.012↗
- Case of a Patient With Pancreatic Cancer With Sporadic Microsatellite Instability Associated With a BRAF Fusion Achieving Excellent Response to Immunotherapy. Co-author DOI 10.1200/po.22.00650↗
Closest collaborators
The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Christoph Benedikt Westphalen · 6 shared papers, 2023–2025 · strength 0.97
- Paper Sustained Clinical Response to Olaparib in a Patient with Metastatic Pancreatic Cancer and Somatic ATM Mutation R2034Te… DOI 10.1159/000545975↗
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
- Paper Case of a Patient With Pancreatic Cancer With Sporadic Microsatellite Instability Associated With a BRAF Fusion Achievi… DOI 10.1200/po.22.00650↗
- Volker Heinemann · 4 shared papers, 2023–2025 · strength 0.68
- Paper Sustained Clinical Response to Olaparib in a Patient with Metastatic Pancreatic Cancer and Somatic ATM Mutation R2034Te… DOI 10.1159/000545975↗
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
- Paper Case of a Patient With Pancreatic Cancer With Sporadic Microsatellite Instability Associated With a BRAF Fusion Achievi… DOI 10.1200/po.22.00650↗
- Georg Beyer · 3 shared papers, 2023–2025 · strength 0.50
- Paper Sustained Clinical Response to Olaparib in a Patient with Metastatic Pancreatic Cancer and Somatic ATM Mutation R2034Te… DOI 10.1159/000545975↗
- Paper Case of a Patient With Pancreatic Cancer With Sporadic Microsatellite Instability Associated With a BRAF Fusion Achievi… DOI 10.1200/po.22.00650↗
- Paper Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. DOI 10.1007/s11523-023-00950-0↗
- Simon Sirtl · 2 shared papers, 2023–2025 · strength 0.36
- Maximilian Niyazi · 2 shared papers, 2023–2025 · strength 0.34
- Julia V. Mayerle · 2 shared papers, 2023–2025 · strength 0.34
- Danmei Zhang · 2 shared papers, 2023–2024 · strength 0.32
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
- Paper Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. DOI 10.1007/s11523-023-00950-0↗
- Michael Haas · 2 shared papers, 2023–2024 · strength 0.32
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
- Paper Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. DOI 10.1007/s11523-023-00950-0↗
- Lena Weiss · 2 shared papers, 2023–2024 · strength 0.32
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
- Paper Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. DOI 10.1007/s11523-023-00950-0↗
- Klara Dorman · 2 shared papers, 2023–2024 · strength 0.32
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
- Paper Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. DOI 10.1007/s11523-023-00950-0↗
- Stefan Hubert Boeck · 2 shared papers, 2023–2024 · strength 0.32
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
- Paper Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. DOI 10.1007/s11523-023-00950-0↗
- Steffen Ormanns · 2 shared papers, 2023 · strength 0.29
- Paper Case of a Patient With Pancreatic Cancer With Sporadic Microsatellite Instability Associated With a BRAF Fusion Achievi… DOI 10.1200/po.22.00650↗
- Paper Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. DOI 10.1007/s11523-023-00950-0↗
- Frederick Klauschen · 2 shared papers, 2023 · strength 0.29
- Paper Case of a Patient With Pancreatic Cancer With Sporadic Microsatellite Instability Associated With a BRAF Fusion Achievi… DOI 10.1200/po.22.00650↗
- Paper Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. DOI 10.1007/s11523-023-00950-0↗
- Bernhard Willibald Renz · 2 shared papers, 2023 · strength 0.28
- Jens Werner · 2 shared papers, 2023 · strength 0.28
- Marlies Vornhülz · 1 shared paper, 2025 · strength 0.21
- Paul Rogowski · 1 shared paper, 2025 · strength 0.21
- Alexander Kleger · 1 shared paper, 2025 · strength 0.21
- Victoria Probst · 1 shared paper, 2024 · strength 0.18
- Dirk Waldschmidt · 1 shared paper, 2024 · strength 0.18
- Michael Quante · 1 shared paper, 2024 · strength 0.18
- Enrico Narciso De Toni · 1 shared paper, 2023 · strength 0.16
- Alexandr V. Bazhin · 1 shared paper, 2023 · strength 0.15
- Matthias Ilmer · 1 shared paper, 2023 · strength 0.15
- Ivonne Regel · 1 shared paper, 2023 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.